Description
URIDOT-0.4 Tablet contains Tamsulosin 0.4mg in a modified-release formulation, an alpha-1 adrenergic receptor blocker used to relieve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. It helps relax smooth muscle in the prostate and bladder neck, making urination easier for eligible patients.
Tamsulosin may help reduce symptoms such as a weak urine stream, difficulty starting urination, interrupted flow and the sensation of incomplete bladder emptying. It helps manage symptoms but does not shrink the prostate or cure BPH. Persistent urinary symptoms require clinical assessment because other conditions may cause similar problems.
CardianCare provides a contact point for pharmaceutical product and trade enquiries. Businesses searching for a Tamsulosin 0.4mg modified-release Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing-source information and applicable quality documentation.
For procurement teams evaluating a Tamsulosin 0.4mg modified-release Tablets manufacturer and supplier India, important considerations include composition accuracy, release characteristics, product authorization, packaging, batch traceability, shelf life and storage requirements.
2. Key Ingredient
Composition:
Tamsulosin 0.4mg Modified Release
Tamsulosin is an alpha-1 adrenergic receptor antagonist, commonly described as an alpha-blocker. It acts mainly on alpha-1 receptors in smooth muscle around the prostate and bladder neck.
By relaxing this smooth muscle, tamsulosin helps reduce resistance to urine flow and can improve urinary symptoms associated with BPH. The modified-release formulation is designed to release the active ingredient according to its approved formulation characteristics.
Businesses researching a Tamsulosin 0.4mg modified-release pharmaceutical company India should assess product specifications, approved labelling, product authorization, release characteristics and applicable quality documentation.
Companies evaluating a Tamsulosin 0.4mg modified-release medicine manufacturer India should verify the legal manufacturing source, regulatory status, batch documentation and formulation-specific quality requirements before procurement.
3. Key Benefits
Urinary symptom relief: Helps relieve lower urinary tract symptoms associated with benign prostatic hyperplasia.
Improved urine flow: Relaxes smooth muscle around the prostate and bladder neck, reducing resistance to urine flow.
Support for urinary comfort: May help reduce difficulty starting urination, weak flow and interrupted urination.
Modified-release formulation: Designed to release the active ingredient according to the approved formulation characteristics.
Symptom-management option: Offers a medical treatment option for eligible patients with BPH-related urinary symptoms.
Clinician-guided treatment: Can be incorporated into an individualized treatment plan following appropriate assessment.
Response varies between patients. Tamsulosin treats urinary symptoms but does not eliminate prostate enlargement or rule out other urinary conditions.
Pharmaceutical buyers searching for a Tamsulosin 0.4mg modified-release supplier India should verify product authenticity, current availability, approved specifications, shelf life and supporting documentation.
A Tamsulosin 0.4mg modified-release Tablet wholesaler and distributor India enquiry may cover stock availability, minimum order quantities, delivery coverage, licensing requirements and applicable commercial terms.
Businesses seeking a Tamsulosin 0.4mg modified-release bulk supplier India should request a formal quotation and confirm packaging specifications, storage conditions, batch traceability and quality documentation.
A Tamsulosin 0.4mg modified-release pharmaceutical distributor India should verify distribution eligibility, product authorization and approved promotional information before beginning commercial activities.
4. How Does It Work?
Tamsulosin selectively blocks alpha-1 adrenergic receptors in smooth muscle, particularly in the prostate and bladder neck. This reduces smooth-muscle tension and helps lower the resistance encountered by urine as it passes through the urinary tract.
The resulting relaxation can improve urinary flow and reduce symptoms associated with BPH. Tamsulosin does not directly shrink the prostate, and it does not treat prostate cancer or other causes of urinary obstruction.
Because tamsulosin can lower blood pressure in some patients, dizziness and postural hypotension may occur, particularly when standing up from a seated or lying position.
5. Directions for Use
Dosage: Take only as prescribed by a doctor. The appropriate regimen must follow the approved product information and the patient’s clinical needs.
Administration: Follow the instructions on the approved pack. Many modified-release tamsulosin products are taken after the same meal each day; exact instructions depend on the specific formulation.
Swallowing: Swallow the Tablet or capsule as directed by the product leaflet. Do not crush, chew or split a modified-release dosage form unless the approved instructions specifically permit it.
Consistent timing: Maintain a consistent daily schedule according to the doctor’s instructions.
Missed dose: Follow the patient leaflet or advice from a healthcare professional. Do not double the next dose.
Dizziness precautions: Rise slowly from sitting or lying positions, especially when beginning treatment. Avoid driving if dizziness or faintness occurs.
Follow-up: Seek medical assessment if symptoms worsen, urinary retention develops or treatment does not provide adequate relief.
The precise administration instructions should be confirmed against the approved pack because modified-release formulations may differ.
6. Possible Side Effects
Possible side effects include:
Dizziness or light-headedness
Abnormal ejaculation, including reduced or absent ejaculation
Headache
Runny or blocked nose
Weakness
Postural hypotension, particularly when standing up
Important safety concerns
Fainting: Severe dizziness or loss of consciousness requires prompt medical assessment.
Low blood pressure: The risk may increase when tamsulosin is taken with other medicines that lower blood pressure.
Allergic reactions: Rash, swelling or difficulty breathing requires urgent medical attention.
Priapism: A prolonged, painful erection is a medical emergency and requires immediate treatment.
Eye surgery considerations: Tamsulosin use has been associated with intraoperative floppy iris syndrome during cataract or glaucoma surgery. Inform the eye surgeon about current or previous use.
This list is not exhaustive. Patients should report persistent or concerning symptoms to a healthcare professional.
7. Safety Information
Medical supervision: Use only under the guidance of a qualified healthcare professional.
Contraindications: Follow the approved product information. Do not use in patients with known serious hypersensitivity to tamsulosin or any formulation ingredient.
Blood pressure: Use caution in patients with low blood pressure or a history of postural hypotension.
Liver and kidney health: Inform the prescriber about liver or kidney disease. suitability and precautions depend on the severity of the condition and the approved product information.
Drug interactions: Tell the doctor about all medicines, particularly other alpha-blockers, blood pressure medicines, phosphodiesterase-5 inhibitors such as sildenafil or tadalafil, and medicines that affect CYP3A4 or CYP2D6 enzymes.
Cataract or glaucoma surgery: Inform the ophthalmologist about current or previous tamsulosin use before eye surgery.
Pregnancy and breastfeeding: This medicine is generally intended for male patients with BPH-related symptoms and is not indicated for routine use during pregnancy or breastfeeding. Consult a healthcare professional if there is any question about its use.
Prostate assessment: A doctor may need to assess other causes of urinary symptoms, including urinary infection, urinary retention or prostate cancer, as clinically appropriate.
Storage: Keep the medicine in its original packaging and follow the approved label’s storage instructions. Protect it from excessive heat and moisture as directed, and keep it out of children’s reach.
This information is educational and does not replace approved prescribing information or individualized medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare provides a contact point for pharmaceutical product and trade enquiries. Doctors, pharmacists, procurement teams, wholesalers, distributors and eligible pharmaceutical business partners can contact the company to ask about current product availability and applicable commercial arrangements.
Businesses researching a Tamsulosin 0.4mg modified-release PCD pharma franchise India opportunity should confirm directly whether the product and a relevant programme are available, including territory eligibility, partner requirements and commercial terms.
For a Tamsulosin 0.4mg modified-release Tablets PCD pharma franchise enquiry, prospective partners can request information about product availability, minimum order quantities, licensing requirements, distribution eligibility and any applicable promotional support.
Companies exploring a Tamsulosin 0.4mg modified-release Tablet PCD franchise should verify programme availability and product eligibility before making investment or promotional commitments.
Businesses evaluating Tamsulosin 0.4mg modified-release third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Due diligence should include manufacturing authorization, applicable GMP compliance, product approvals, modified-release formulation controls and quality documentation.
A Tamsulosin 0.4mg modified-release Tablet third party manufacturer India enquiry should cover the manufacturing facility’s regulatory status, formulation controls, quality systems, batch-release procedures, packaging specifications and contractual responsibilities.
Companies investigating Tamsulosin 0.4mg modified-release contract manufacturing India should confirm service availability and discuss formulation specifications, release-profile requirements, technical documentation, quality agreements, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.
Contact CardianCare through its official website to enquire about current product availability, pharmaceutical distribution opportunities and applicable business arrangements. PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly before being represented as available.
9. For More Information
For more information about URIDOT-0.4 Tablet (Tamsulosin 0.4mg Modified Release), click here












Reviews
There are no reviews yet.